Pharmaceutical applications of powder-based binder jet 3D printing process – A review

• Published in: Advanced drug delivery reviews Vol. 177; p. 113943
• Main Authors: Sen, Koyel, Mehta, Tanu, Sansare, Sameera, Sharifi, Leila, Ma, Anson W.K., Chaudhuri, Bodhisattwa
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-10-2021
• Subjects: 3D printing; Binder-jet; Excipients - chemistry; Pharmaceutical dosage form; Powders - chemistry; Printing, Three-Dimensional; Solid oral dosage form; Technology, Pharmaceutical - methods; Binder-jet; 3D; Solid oral dosage form; API; DAMPP; 3D printing; Pharmaceutical dosage form; HPMC
• ISSN: 0169-409X; 1872-8294
• DOI: 10.1016/j.addr.2021.113943

[Display omitted]
Pharmaceutical applications of the 3D printing process have recently matured, followed by the FDA approval of Spritam, the first commercial 3D printed dosage form. Due to being a new technology in the conventional dosage formulation field, there is still a dearth of understanding in the 3D printing process regarding the effect of the raw materials on the printed dosage forms and the plausibility of using this technology in dosage development beyond the conventional ways. In this review, the powder-based binder jet 3D printing (BJ3DP) process and its pharmaceutical applications have been discussed, along with a perspective of the formulation development step. The recent applications of BJ3DP in pharmaceutical dosage development, the advantages, and limitations have further been discussed here. A discussion of the critical formulation parameters that need to be explored for the preformulation study of the solid oral dosage development using the BJ3DP process is also presented.